

ALASKA MEDICAID

**Adcirca® (tadalafil)**

Tablet: 20mg

**PREFERRED DRUG:**

NA

**NON-PREFERRED DRUG:**

NA

**INDICATION:**

“ADCIRCA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (WHO Group I) to improve exercise ability.”<sup>1</sup>

**CRITERIA FOR APPROVAL:**

1. The patient has been diagnosed with pulmonary arterial hypertension (WHO Group I); **AND**
2. The patient is not currently being treated any nitrate product.

**CRITERIA CAUSING DENIAL:**

1. The patient is on any nitrate product.

**DISPENSING LIMIT:**

1. The dispensing limit is a 30 day supply of the medication.

**QUANTITY LIMIT:**

1. The quantity limit per 30 days is 60 tablets.

**REFERENCES / FOOTNOTES:**

<sup>1</sup> Adcirca® package insert, available at: <<http://www.adcirca.com/pdf/Adcirca-PI.pdf>>  
Accessed 02/09/2010.